A leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing.

Technology platforms that span the entire drug discovery to manufacturing spectrum, including novel, industry-leading systems and tools for continuous manufacturing and the development of cell lines, bispecific antibodies, and antibody drug conjugates. 

Unparalleled capacities and expertise for the discovery, development and cGMP manufacture of biologics from mammalian cell culture. We offer integrated programs utilizing 6 discovery platforms, one of the largest global CMC development teams and an extensive drug substance and drug product supply chain network across multiple countries.

Comprehensive CMC development and cGMP manufacturing microbial fermentation platform. 

E. coli and yeast-based expression systems for the production of plasmid DNA and recombinant proteins. 

Global, one-stop CMC development with multiple and expanding cGMP manufacturing facilities for viral-based products and vaccines.

Comprehensive and integrated discovery, CMC development and cGMP manufacturing platform for Antibody Drug Conjugates (ADCs) and other bioconjugates.  Leading ADC engineering technologies, expertise and quality systems to ensure right-first-time  project execution.

WuXi Biologics provides extensive expertise and high-quality biosafety testing under EMA, ISO (CNAS) and CMA certified laboratories and full analytical development and QC labor atories approved by U.S. FDA, EMA and NMPA.

World-class quality systems approved by the U.S. FDA, EMA and the first organization in China to be approved for production of a commercial bio therapeutic.